Zelira Therapeutics Limited (ASX: ZLD) has announced that last patient has completed dosing in its pioneering medicinal cannabis trial cannabis for insomnia. The company expects to report half-year results by February 2020.
- It is said that no adverse events have been reported to date.
- Centre for Sleep Science – University of Western Australia, has led the clinical trial.
- It is evaluating the safety and efficacy of drugs containing THC and CBD for chronic insomnia.
By 1:35 PM AEDT, ZLD was trading at $0.057, up by 3.63% from the previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.